Orion Office REIT Inc vs Revvity Inc — how do they compare? Orion Office REIT Inc trades at $2.18 (market cap $125.50M), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 135.3× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.64%). Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and Revvity Inc for 12 Days on average.
| ONL | RVTY | |
|---|---|---|
Market Cap | $125.50M | $16.98B |
Volume | 303,276 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $157.36 |
52-Week Low | $1.93 | $82.26 |
Typical Hold Time | 33 Days | 12 Days |
Enterprise Value | $542.43M | $19.30B |
Dividend Yield | 3.64% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.17, down 4.41% today, with a bearish technical signal from moving averages but bullish oscillators. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Valuation metrics include P/S of 0.88 and P/B of 0.2, suggesting potential undervaluation, while analyst consensus is split evenly between Buy and Hold ratings. Recent news highlights strategic portfolio repositioning and a declared $0.02 dividend for H2-26.
Outlook remains challenged by operational losses and high leverage, though deep asset discounts and strategic reviews may offer turnaround potential. Key risks include sustained negative margins, debt servicing pressures, and office sector headwinds. Investment appeal hinges on execution of repositioning efforts and margin recovery.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →